Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1040 results
September 2015
-
Media ReleaseNovartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NETIn pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
-
Media ReleaseNovartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approvalPositive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart failure trial which…
-
Media ReleaseNovartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retiresNew leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
-
Media ReleaseNovartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countriesFirst-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and…
-
Media ReleaseSwissmedic approves Novartis' new heart failure medicine Entresto(TM)Decision by Swiss Health Authority follows US Food and Drug Administration (FDA) approval of Entresto in July, serves as an important reference approval for multiple other health authorities…
-
Media ReleaseNovartis Foundation healthcare models and disease elimination programs showcased at ECTMIHTelemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients Retrospective contact tracing of former leprosy…
-
Media ReleaseNovartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myelomaFarydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD[1] In clinical trials, Farydak…
-
Media ReleaseSandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United StatesLaunch follows March 6, 2015 FDA approval Sandoz One SourceTM offers patient support services The digital press release with multimedia content can be accessed here: Holzkirchen,…
-
Media ReleaseNovartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemiaRevolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments Patients living with SAA, a rare blood disorder,…
-
Media ReleaseNovartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatmentsThe companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule Novartis and Amgen also plan…
-
Media ReleaseNovartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanomaApproval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy Targeted combination offers…
Pagination
- ‹ Previous page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- …
- 87
- › Next page